Steven
Ok, I admit the title of this post lacks specificity, but I took it from the title of the article.
Are you aware of any additional research with the combination? Looks very interesting.
http://www.sciencedaily.com/releases/2013/11/131125121143.htm
I does look very interesting - in mice. I haven't heard of any clinical trials testing this combination (interleukin-12 plus a CTLA-4 antibodies). Note that most trials for checkpoint inhibitors for GBM are going with PD-1 inhibitors (like nivolumab or pembrolizumab) rather that CTLA-4 inhibitors like ipilimumab/Yervoy.
ReplyDeleteFull study available here:
http://jem.rupress.org/content/210/13/2803.full.pdf+html